Medtronic (MDT) delivered quarterly results that exceeded Wall Street expectations and lifted its full-year outlook, sending shares up 6.5% in premarket trading. The gains come after a difficult stretch for one of the world’s largest medical device makers, whose stock had lost more than 30% over the past five years—even with dividends reinvested, the total return remained negative by roughly 20%. Now, with valuation still low and fundamentals showing signs of improvement, investors are beginning to ask whether a broader rerating may be taking shape.
For the fiscal first quarter, Medtronic reported net income of $1.47 billion, or $1.14 per share, compared with $1.04 billion, or $0.81 per share, in the prior-year period. Excluding one-time items, adjusted earnings came in at $1.45 per share, ahead of the $1.39 consensus estimate from analysts surveyed by FactSet. Net sales rose 14% year over year to $9.76 billion, topping the $9.55 billion Wall Street forecast. On an organic basis, sales also increased 14%.
By segment, cardiovascular revenue jumped 20% to $3.93 billion, making it the company’s largest top-line contributor. Neuroscience sales grew 10% to $2.68 billion, while the medical-surgical unit posted a 10% increase to $2.28 billion. Chief Financial Officer Thierry Piéton attributed the stronger-than-expected results to solid operating performance and disciplined financial management, which gave management confidence to raise guidance.
Medtronic now projects full-year adjusted earnings per share between $5.94 and $6.00, with the low end lifted by 4 cents from the prior range. Organic revenue growth is expected to reach 7.25% to 7.75%, up from the previous forecast of 6.75% to 7.25%.
The company also announced two separate investments totaling approximately $780 million on the same day. Medtronic plans to invest about $700 million in Cornerstone Robotics in exchange for the right to distribute the Sentire surgical system in select international markets. The company said Sentire will complement its own Hugo robotic-assisted surgery platform, giving surgeons and health systems more choices and flexible solutions. A second investment of up to $80 million will go to Pi-Cardia, whose ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve transcatheter aortic valve replacement in patients at risk of coronary obstruction. The agreement includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an upfront price of up to $210 million.
From a valuation standpoint, Medtronic trades at roughly 15 times forward earnings with a dividend yield around 3.4%. In June, the company raised its dividend for the 49th consecutive year, putting it on track to join the Dividend Kings if the streak reaches 50 next year. Analysts’ median price target stands at $100, and no analyst currently rates the stock a sell. Growth is expected to be driven by newer products, including the Affera pulsed field ablation system for atrial fibrillation, the Symplicity Spyral system for treatment-resistant hypertension, and the Hugo robotic-assisted surgery platform. The company is also integrating more artificial intelligence features into its endoscopy module and spinal surgical planning products. Expansion of the robotics and AI pipeline, along with restructuring moves such as the diabetes unit spin-off, could improve free cash flow and free up resources for higher-margin cardiovascular and neuroscience businesses.
Medtronic has faced multiple headwinds in recent years, including rising costs, supply chain disruptions, quality control issues, and a widening gap to Intuitive Surgical in robotic surgery. The emergence of GLP-1 weight-loss drugs has also raised concerns about future demand for surgeries and implants. Yet relative to the S&P 500, which trades at around 29 times earnings, and Intuitive Surgical at roughly 32 times forward earnings, Medtronic still looks inexpensive. That means the stock may not need accelerating growth to stabilize—simply meeting Wall Street’s relatively conservative expectations could be enough to support a recovery.
Earnings that beat estimates, a raised outlook, and new investments in surgical robotics and heart valve technology are providing the catalysts for a potential valuation reset. Whether the recovery can be sustained will depend on the pace of new product adoption, cost control, and the broader market’s appetite for medical device stocks.
